Eduardo Bravo, Chief Executive Officer of Citryll, comments, "Securing funding from such a fantastic range of global life sciences investors, who share our excitement for the potential of CIT-013, strengthens the next steps for our clinical development program. We believe our NET-targeting approach, developed by the company founders... has the potential to be beneficial in conditions where current therapies fall short."
Citryll, founded by ModiQuest B.V. and key figures Helmuth van Es and Renato Chirivi, is pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), which are critical to the inflammatory process.
Collection
[
|
...
]